Published in Health Business Week, October 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Spectrum Pharmaceuticals, Inc.
Report 1: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA should wait for the overall survival analysis of satraplatin.
"We have confidence the final data analysis of overall survival will demonstrate the efficacy and safety of satraplatin for the treatment of hormone-refractory prostate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.